While the price surge in shares of Selecta Biosciences (NASDAQ:SELB) receded slightly on October 26 with the stock rising only 10.6% to close at $3.13 per share, strong insider buying and a rare pediatric disease designation may maintain the upward […]
This content is for members only
After the market closed on June 11, Selecta Biosciences, Inc. (NASDAQ:SELB) announced it had entered a licensing deal with $SOBI (STO:SOBI), granting most of the global rights to Selecta’s phase III gout drug, SEL-212, to SOBI. Selecta’s stock fell about […]
This content is for members only